| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
|
Lordick, F.
|
|
|
36 |
2 |
p. 197-207
|
artikel
|
| 2 |
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
|
Baron, D.
|
|
|
36 |
2 |
p. 208-215
|
artikel
|
| 3 |
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
|
Hortobagyi, G.N.
|
|
|
36 |
2 |
p. 149-157
|
artikel
|
| 4 |
Authors’ reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study
|
Conroy, T.
|
|
|
36 |
2 |
p. 216-218
|
artikel
|
| 5 |
Chi-square and P-values versus machine learning feature selection
|
Takefuji, Y.
|
|
|
36 |
2 |
p. 227-228
|
artikel
|
| 6 |
Circulating tumor DNA after definitive therapy for locally advanced rectal cancer
|
Sorscher, S.
|
|
|
36 |
2 |
p. 223-224
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
36 |
2 |
p. iii
|
artikel
|
| 8 |
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
|
Harter, P.
|
|
|
36 |
2 |
p. 185-196
|
artikel
|
| 9 |
Estrogens and breast cancer
|
Kim, J.
|
|
|
36 |
2 |
p. 134-148
|
artikel
|
| 10 |
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
|
Carausu, Marcela
|
|
|
36 |
2 |
p. 127-129
|
artikel
|
| 11 |
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
|
Huppert, L.A.
|
|
|
36 |
2 |
p. 172-184
|
artikel
|
| 12 |
PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?
|
Nishimura, T.
|
|
|
36 |
2 |
p. 220-221
|
artikel
|
| 13 |
Promising response to lurbinectedin in NUT carcinoma: a case report and review of emerging therapeutic strategies
|
Sánchez Becerra, M.V.
|
|
|
36 |
2 |
p. 225-227
|
artikel
|
| 14 |
Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima
|
Bercz, A.
|
|
|
36 |
2 |
p. 224-225
|
artikel
|
| 15 |
Reply to the Letter to the Editor “Odronextamab against relapsed or refractory follicular lymphoma” by Y. Shimazu
|
Kim, T.M.
|
|
|
36 |
2 |
p. 222-223
|
artikel
|
| 16 |
Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’
|
Fraunhoffer, N.
|
|
|
36 |
2 |
p. 228-229
|
artikel
|
| 17 |
Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto
|
Felip, E.
|
|
|
36 |
2 |
p. 221-222
|
artikel
|
| 18 |
Table of Contents
|
|
|
|
36 |
2 |
p. i-ii
|
artikel
|
| 19 |
The immunotherapy challenge in locally advanced gastroesophageal cancer: VESTIGE trial’s insights and future pathways
|
Nakayama, I.
|
|
|
36 |
2 |
p. 130-133
|
artikel
|
| 20 |
Time to rethink platinum choices in the era of immunotherapy in lung cancer
|
Harris, E.
|
|
|
36 |
2 |
p. 218-220
|
artikel
|
| 21 |
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy ☆
|
Martín, M.
|
|
|
36 |
2 |
p. 158-171
|
artikel
|
Tijdschrift beschrijving